Rhythm Pharmaceuticals, Inc.
Clinical trials sponsored by Rhythm Pharmaceuticals, Inc., explained in plain language.
Biopharmaceutical company developing therapies for rare genetic obesity disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to curb hunger in Prader-Willi syndrome Results expected Oct 2026 (estimated) May already have reported ↗
- Hope for hypothalamic obesity: daily shot targets weight and hunger Results expected Mar 2027 (estimated) May already have reported ↗ 🚀 Make-or-break
-
Hope for hypothalamic obesity: daily shot targets weight and hunger
Disease control Recruiting nowThis phase 3 trial tests whether a daily injection of setmelanotide can help people aged 4 and older with hypothalamic obesity lose weight and feel less hungry. Participants will receive either the drug or a placebo for 26 weeks. The study aims to see if the treatment leads to me…
Phase 3 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New weekly shot aims to curb obesity in rare genetic disorders
Disease control Recruiting nowThis study tests a weekly injection called RM-718 in healthy people with obesity and in patients with obesity caused by problems in the MC4R pathway, including hypothalamic obesity and Prader-Willi syndrome. The main goal is to check the drug's safety and how the body processes i…
Phase 1/2 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC